Welcome to our dedicated page for BioCardia Warrant SEC filings (Ticker: BCDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. (BCDAW) filings document material events, operating results, and corporate disclosures for a company developing cellular and cell-directed therapeutics for cardiovascular and pulmonary diseases. Recent 8-K reports include results of operations and financial condition, regulatory updates for the CardiAMP Cell Therapy System and Helix Transendocardial Delivery Catheter, and intellectual-property disclosure for radial and trans-endocardial delivery catheter technology.
The filings also record material agreements and commercialization activity, including Heart3D Fusion Imaging, a cardiac-intervention guidance system that fuses two-dimensional x-ray imaging with annotated three-dimensional heart models from MRI and CT images. Disclosure categories include capital structure, shareholder voting matters, governance, security-structure matters, exhibits, and furnished press-release information.